Centiva Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Centiva Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,753	Closed	-$204K	–	917
2020 Q2	$204K	Buy	+8,753	New	+$127K	0.01%	526

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Centiva Capital's VIVO Position: Q3 2020 in Review

Centiva Capital sold out of Meridian Bioscience Inc (VIVO) in Q3 2020, closing a stake of 8,753 shares — an estimated $204K sold.

Centiva Capital first reported a position in VIVO in Q2 2020 and held it in 1 quarter. The position peaked at $204K in Q2 2020. 191 funds tracked by Wall St. Rank hold VIVO as of Q3 2020.

Centiva Capital reported no remaining Meridian Bioscience Inc position as of Q3 2020 after selling out during the quarter.
Centiva Capital sold 8,753 Meridian Bioscience Inc shares in Q3 2020, an estimated $204K.
Centiva Capital first reported a position in Meridian Bioscience Inc in Q2 2020 and held it in 1 quarter.
Centiva Capital's Meridian Bioscience Inc position peaked at $204K in Q2 2020.
191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2020.

Based on Centiva Capital's 13F filing for Q3 2020, filed 16 Nov 2020.